Company overview. Government Employees Health Association, Inc., commonly known as GEHA, is a not-for-profit, member association founded in 1937 and headquartered at 310 NE Mulberry Street, Lee's Summit, Missouri. It is a tax-exempt 501(c)(9) voluntary employees' beneficiary association; it is privately held with no public ticker and no parent company. Its most recent IRS Form 990 filings report roughly 1,500–1,700 employees and total revenue of about $5.7 billion (FY2023) and $6.1 billion (FY2024); the organization also reports roughly $2.6 billion in total assets. GEHA is not a patent-holding entity.
Products / services. GEHA is a health benefits carrier, not a technology company. It offers medical plans to federal employees, annuitants and their dependents through the Federal Employees Health Benefits Program (FEHB), including standard-option, high-option and high-deductible health plan designs, and dental and vision plans through the Federal Employees Dental and Vision Insurance Program (FEDVIP). It also markets supplemental products and discount/wellness programs, and serves military retirees. Its revenue comes almost entirely from program service revenue (insurance premiums), which is why it appears in litigation as a payor and reimbursement entity.
Patent-litigation posture. The tracked data show three cases, all as plaintiff and zero as defendant — the opposite of the NPE pattern. GEHA is not asserting patents; it is using the courts as a purchaser/payor challenging pharmaceutical patent and generic-entry conduct. Two suits were filed on 2020-06-23 in the Northern District of Illinois against Jazz Pharmaceuticals PLC, and a third was filed in the Northern District of California. Venue is not the plaintiff-friendly Eastern District of Texas; these are the parties' home and MDL forums.
Notable cases and context. All three tracked matters are Xyrem/sodium oxybate antitrust actions against Jazz Pharmaceuticals, arising from alleged pay-for-delay settlements with generic manufacturers and Orange Book patent listings. GEHA's California action was consolidated into In re Xyrem (Sodium Oxybate) Antitrust Litigation, MDL No. 2966 (N.D. Cal.), where GEHA is among class plaintiffs, including health benefit plan payors. A settlement in that MDL received final court approval in October 2025. The Illinois complaints assert parallel state and federal antitrust claims.